Bladder Cancer

Bladder cancer is a serious and potentially aggressive disease affecting the urinary bladder's lining, often leading to symptoms such as blood in the urine, frequent urination, and pelvic pain. If untreated, the cancer can spread to nearby organs or other parts of the body, resulting in complications and impacting a patient's quality of life.

Advances in the molecular understanding of bladder cancer have led to more targeted therapies that go beyond symptom management, focusing on the specific pathways driving cancer growth. These targeted treatments aim to slow disease progression and improve patient outcomes by addressing the root causes of the cancer.

iNGENū’s team of researchers and clinicians is dedicated to advancing bladder cancer research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by bladder cancer.

 

2x

increase in risk for bladder cancer with exposure to secondhand smoke

 

 

90%

of cases originate in the urothelial cells.

 

 

4.6%

of all cancer cases are bladder cancers





Our clinical team has over

120

years of combined clinical trial experience

Download Our Paper

Fill out this form to download our white paper on how to overcome the biggest obstacles in conducting a Bladder Cancer Clinical Trial.

iNGENu CRO - Bladder Cancer Clinical Trials-1

In light of the impact Bladder Cancer has on individuals and society as a whole, continued research efforts are crucial to improve diagnosis, treatment, and ultimately, patients' quality of life.

The development of clinical trial protocols that meet FDA approval standards is crucial for the success of new Bladder Cancer treatments.